UCB SA
UCB
UCB SA is a Belgium-based biopharmaceutical company focused on neurology and immunology. The portfolio includes established epilepsy therapies and newer biologics such as bimekizumab for dermatology indications, complemented by rare-disease assets. Operations are global with meaningful exposure to Europe and the United States. Strategy centers on targeted R&D, disciplined launches, and selective bolt-on acquisitions.
Quant
3.3
Qual
3.2
Gov
3.4